Trusted Resource for Clinical Trials, Protocols & Progress
An Abbreviated New Drug Application (ANDA) is the regulatory mechanism by which pharmaceutical companies gain approval to market generic versions of previously approved innovator drugs. The process is governed by the U.S. Food and Drug Administration (FDA) under Section 505(j) of the Federal Food, Drug, and Cosmetic Act.
Click to read the full article.
Bioequivalence (BE) forms the cornerstone of an Abbreviated New Drug Application (ANDA) because it demonstrates that the proposed generic drug performs in the same manner as the reference listed drug (RLD). The U.S. Food and Drug Administration (FDA) mandates BE evidence to ensure therapeutic equivalence without requiring extensive clinical trials.
Click to read the full article.
A Drug Master File (DMF) is a confidential submission to the U.S. Food and Drug Administration (FDA) that provides detailed information about the manufacturing, processing, packaging, and storing of a drug substance or drug product. In the context of Abbreviated New Drug Applications (ANDAs), DMFs—particularly Type II (for drug substances)—play a pivotal role in enabling generic drug applicants to cross-reference critical data held by an Active Pharmaceutical Ingredient (API) manufacturer.
Click to read the full article.
The Hatch-Waxman Act, formally known as the Drug Price Competition and Patent Term Restoration Act of 1984, created a regulatory pathway for generic drugs while preserving the intellectual property rights of brand-name manufacturers. It established the Abbreviated New Drug Application (ANDA) process and introduced the critical concepts of patent certification and marketing exclusivity.
Click to read the full article.
Generic drug applicants must demonstrate bioequivalence to a Reference Listed Drug (RLD) as part of an Abbreviated New Drug Application (ANDA). This bioequivalence can be shown through either:
Click to read the full article.
A Complete Response Letter (CRL) is the U.S. FDA’s formal communication indicating that an Abbreviated New Drug Application (ANDA) or New Drug Application (NDA) cannot be approved in its present form. For generic drug sponsors, a CRL is not a denial but rather a request to address specific deficiencies identified during the review process.
Click to read the full article.
Under the Hatch-Waxman Act, the U.S. FDA grants a special marketing incentive to the first applicant who files a substantially complete Abbreviated New Drug Application (ANDA) containing a Paragraph IV certification against a patent listed for a Reference Listed Drug (RLD). This incentive comes in the form of a 180-day exclusivity period, during which no other generic version of the same drug can be marketed.
Click to read the full article.
Generic drugs account for over 80% of prescriptions filled in the United States and a significant portion of medicines dispensed across the European Union (EU). Despite a shared objective—to provide safe, effective, and lower-cost alternatives to brand-name drugs—the regulatory pathways for generic drug approval in the U.S. and EU vary substantially.
Click to read the full article.
Antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), represent a vital class of CNS drugs with widespread use. The regulatory approval of a generic version of an antidepressant drug requires robust bioequivalence (BE) data, precise formulation replication, and special considerations for therapeutic equivalence.
Click to read the full article.
Product-Specific Guidances (PSGs) are FDA-issued documents that provide detailed recommendations on the design of bioequivalence (BE) studies and other development considerations for individual drug products. They are essential tools for generic drug manufacturers planning to submit an Abbreviated New Drug Application (ANDA).
Click to read the full article.
